Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14137 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Louis Nevejan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 32 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Barely two per million Belgian children/adolescents are diagnosed with chronic myeloid leukemia (CML) annually. In this retrospective study, we aimed to investigate the diagnostic features, clinical and laboratory characteristics, and treatment outcome of this rare entity.
Methods
Medical records of all pediatric CML patients (age ≤ 17 years) diagnosed at the University Hospitals Leuven between 1986 and 2021 were reviewed.
Results
Fourteen patients (median age at diagnosis 12.5 years) were included, all presenting in chronic phase. Five patients were diagnosed before 2003; main therapy included hydroxyurea ( n = 5/5), interferon‐alfa ( n = 3/5) and allogeneic hematopoietic stem cell transplantation (allo‐Tx) ( n = 3/5). Complete hematologic response (CHR), complete cytogenetic response (CCyR) and major molecular response (MMR) was reached in resp. 4/5, 4/5 and in 2/3 of evaluable patients. Three patients progressed to accelerated/blast phase (median time 19 months) and 1/5 is alive and disease‐free at last follow‐up. Nine patients were diagnosed after 2003 and were treated with first generation (1°G) tyrosine kinase inhibitors (TKI): 3/9 subsequently underwent an allo‐Tx, 4/9 were switched to 2°G TKI, one patient was additionally switched to 3°G TKI. CHR, CCyR and MMR was reached in 9/9, 9/9 and 8/9 of these patients. No progression to accelerated/blast phase was observed and none of these patients deceased. At last follow‐up, 7/9 patients were in MMR or disease free, the two remaining patients did not reach or lost MMR, both related to compliance issues.
Conclusion
Our study confirmed that TKI significantly improved the prognosis of pediatric CML. However, drug compliance poses a considerable challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of Paediatrics, Paediatric Haematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.
- Department of Oncology, Laboratory of Experimental Hematology, University of Leuven, Leuven, Belgium.
ORCID-Profile: Louis Nevejan, Veerle Labarque, Nancy Boeckx
Zitieren
APA
Nevejan, L., Labarque, V., & Boeckx, N. (2024). Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings. European Journal of Haematology. https://doi.org/10.1111/ejh.14137
Vancouver
Nevejan L, Labarque V, Boeckx N. Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings. European Journal of Haematology. 2024. doi:10.1111/ejh.14137
BibTeX
@article{Nevejan2024,
author = {Nevejan, Louis and Labarque, Veerle and Boeckx, Nancy},
title = {Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14137}
}
EUVIMED